Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

Key Takeaways RHHBY's phase III FENhance 1 met its primary endpoint in relapsing MS.Fenebrutinib cut RMS relapses 51% vs. teriflunomide; FENhance 2 showed a 59% reduction.RHHBY plans regulatory filings after consistent benefits across RMS and PPMS studies.Roche (RHHBY) recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met its primary endpoint.Fenebrutinib is an experimental oral, central nervous system-penetrant, reversible and non-cova ...